OTCMKTS:GNMSFGenmab A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $352.69 +1.79 (+0.51 %) (As of 07/10/2020 03:25 PM ET) Add Compare Share Today's Range$352.69Now: $352.69▼$358.3650-Day Range$278.04MA: $309.05▼$342.3452-Week Range$159.45Now: $352.69▼$358.36Volume320 shsAverage Volume1,915 shsMarket Capitalization$21.76 billionP/E Ratio64.60Dividend YieldN/ABeta0.67 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genmab A/S. Previous Next 1.9 Community Rank Outperform VotesGenmab A/S has received 160 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenmab A/S has received 259 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenmab A/S has received 61.81% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote “Outperform” if you believe GNMSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.04% of the stock of Genmab A/S is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 64.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 64.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.32.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.38 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNMSF Previous Symbol CUSIPN/A CIKN/A Webwww.genmab.com Phone45-7020-2728Debt Debt-to-Equity Ratio0.01 Current Ratio19.04 Quick Ratio19.04Price-To-Earnings Trailing P/E Ratio64.60 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$804.57 million Price / Sales27.04 Cash Flow$5.63 per share Price / Cash Flow62.64 Book Value$34.13 per share Price / Book10.33Profitability EPS (Most Recent Fiscal Year)N/A Net Income$324.68 million Net Margins41.65% Return on Equity19.10% Return on Assets17.83%Miscellaneous Employees377 Outstanding Shares61,690,000Market Cap$21.76 billion Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable OTC:GNMSF Rates by TradingView Receive GNMSF News and Ratings via Email Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions How has Genmab A/S's stock been impacted by COVID-19 (Coronavirus)? Genmab A/S's stock was trading at $211.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNMSF shares have increased by 67.1% and is now trading at $352.69. View which stocks have been most impacted by Coronavirus. When is Genmab A/S's next earnings date? Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Genmab A/S. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Wednesday, May, 6th. The company reported $0.60 earnings per share for the quarter. The company had revenue of $131.69 million for the quarter. Genmab A/S had a return on equity of 19.10% and a net margin of 41.65%. View Genmab A/S's earnings history. Has Genmab A/S been receiving favorable news coverage? Headlines about GNMSF stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genmab A/S earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Genmab A/S. Who are some of Genmab A/S's key competitors? Some companies that are related to Genmab A/S include Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bayer (BAYRY), Zoetis (ZTS), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), UCB (UCBJF), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY) and Beigene (BGNE). View all competitors. Who are Genmab A/S's key executives? Genmab A/S's management team includes the following people: Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)Mr. David A. Eatwell, Exec. VP & CFO (Age 58)Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)Ms. Jane Juel, Sr. Director of Operations & Resource ManagementMr. Peter Ros, Sr. Director of Fin. & Accounting What is Genmab A/S's stock symbol? Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF." How do I buy shares of Genmab A/S? Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genmab A/S's stock price today? One share of GNMSF stock can currently be purchased for approximately $352.69. How big of a company is Genmab A/S? Genmab A/S has a market capitalization of $21.76 billion and generates $804.57 million in revenue each year. Genmab A/S employs 377 workers across the globe. What is Genmab A/S's official website? The official website for Genmab A/S is www.genmab.com. How can I contact Genmab A/S? Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
